Skip to main content
. 2017 Mar 9;4(4):246–265. doi: 10.1002/acn3.399

Figure 1.

Figure 1

CN‐105 confers survival benefit in ischemic stroke. Intravenous CN‐105 confers survival benefit at 3 days (A) when administered via a single dose at 30 min post reperfusion, and via 2 doses at 30 min and 4.5 h post reperfusion, utilizing the murine model of transient middle cerebral artery occlusion (tMCAO) of 30 min ischemic occlusion time. (*P < 0.05 by log‐rank test compared to vehicle).